From a press release from the company…
Lorus Therapeutics Inc. (‘Lorus’), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced a plan for a new clinical investigation of GTI-2040 as a single-agent in patients with high grade myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Source: Yahoo News
This entry was posted by David Austin on Wednesday, June 28th, 2006 at
12:50 pm and is filed under
Leukemia .
You can follow any responses to this entry through the
RSS 2.0 feed.
You can leave a response, or trackback from your own site.